Medical Health & Life Science Research News

Wilms tumor protein pipeline review, H1 2017 illuminated by new report

Wilms tumor protein pipeline review, H1 2017 illuminated by new report

HTF Market Intelligence released a new research report of 66 pages on title 'Wilms Tumor Protein (WT33 or WT1) - Pipeline Review, H1 2017' with detailed analysis, forecast and strategies. The study covers key regions that includes United States, EU, Japan, China, India and Southeast Asia and important players such as Sumitomo Dainippon Pharma Co Ltd, Vaximm AG

- Advertisement -
- Membership expired -

Summary

Wilms Tumor Protein (WT33 or WT1) - Pipeline Review, H1 2017
Wilms Tumor Protein (WT33 or WT1) pipeline Target constitutes close to 14 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes.

The latest report Wilms Tumor Protein - Pipeline Review, H1 2017, outlays comprehensive information on the Wilms Tumor Protein (WT33 or WT1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Request a sample report @ www.htfmarketreport.com/sample-rep…ms-tumor-protein 

Wilms Tumor Protein (WT33 or WT1) - Wilms tumor protein is a protein that is encoded by the WT1 gene.

- Advertisement -
- Membership expired -
It plays an important role in cellular development and cell survival.

It plays an essential role for development of the urogenital system. It has a tumor suppressor as well as an oncogenic role in tumor formation.

It regulates the expression of numerous target genes, including EPO.  The molecules developed by companies in Phase II, Phase I and Preclinical stages are 5, 1 and 2 respectively.

Similarly, the universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 4 and 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Myelodysplastic Syndrome, Glioblastoma Multiforme (GBM), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Solid Tumor, Ovarian Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Hematological Tumor, Leukemias, Non-Small Cell Lung Cancer, Pancreatic Cancer, Adrenal Gland Cancer, Fallopian Tube Cancer, Head And Neck Carcinoma, High-Grade Glioma, Lung Cancer, Lymphoma, Malignant Glioma, Malignant Mesothelioma, Malignant Pleural Mesothelioma, Melanoma, Merkel Cell Carcinoma, Metastatic Transitional (Urothelial) Tract Cancer, Multiple Myeloma (Kahler Disease), Neuroblastoma, Ocular Melanoma, Peritoneal Cancer, Renal Cell Carcinoma, Salivary Gland Cancer, Sarcomas, Small Intestine Cancer, Soft Tissue Sarcoma, Testicular Cancer, Thymic Carcinoma and Thymoma (Thymic Epithelial Tumor).

Furthermore, this report also reviews key players involved in Wilms Tumor Protein (WT33 or WT1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

- The report provides a snapshot of the global therapeutic landscape for Wilms Tumor Protein (WT33 or WT1)
- The report reviews Wilms Tumor Protein (WT33 or WT1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Wilms Tumor Protein (WT33 or WT1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Wilms Tumor Protein (WT33 or WT1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Wilms Tumor Protein (WT33 or WT1) targeted therapeutics

Access this report @ www.htfmarketreport.com/buy-now?fo…mp;report=498335

Reasons to access

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Wilms Tumor Protein (WT33 or WT1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Wilms Tumor Protein (WT33 or WT1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope

Companies Mentioned in the Report

GlaxoSmithKline Plc
Inovio Pharmaceuticals Inc
Otsuka Holdings Co Ltd
Sumitomo Dainippon Pharma Co Ltd
Vaximm AG

Enquire for [email protected] www.htfmarketreport.com/request-di…ms-tumor-protein

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Wilms Tumor Protein (WT33 or WT1) - Overview
Wilms Tumor Protein (WT33 or WT1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Wilms Tumor Protein (WT33 or WT1) - Therapeutics Assessment
Assessment by Route of Administration
Assessment by Molecule Type
Wilms Tumor Protein (WT33 or WT1) - Companies Involved in Therapeutics Development
GlaxoSmithKline Plc
Inovio Pharmaceuticals Inc
Otsuka Holdings Co Ltd
Sumitomo Dainippon Pharma Co Ltd
Vaximm AG
Wilms Tumor Protein (WT33 or WT1) - Drug Profiles
DSP-7888 - Drug Profile
Product Description

....Continued

View Detailed Table of Content @
www.htfmarketreport.com/reports/49…ms-tumor-protein

News From

HTF Market Intelligence ConsultingHTF Market Intelligence...
Category: Market Research Publishers and RetailersCompany profile: HTF Market Report is wholly owned brand of HTF market Intelligence Consulting Private Limited which provides next-generation service for organizations with a deep focus on market intelligence, data analytics, and social intelligence, all uniquely delivered under one roof by skilled professionals. By combining and analyzing acquire lucid and most relevant data which would help in better decision-making. We provide your requirements with speed and cost benefit across the world, we are able to achi ...

For more information:

Make an Inquiry about this report HERE!
  • www.htfmarketreport.com
  • www.htfmarketreport.com/sample-rep…lms-tumor-protein
  • www.htfmarketreport.com/buy-now?fo…amp;report=498335
  • www.htfmarketreport.com/enquiry-be…lms-tumor-protein
  • www.htfmarketreport.com/reports/49…lms-tumor-protein